16.1 Local Anesthetics, Vasoconstrictors, Dosages & Nerve Block Techniques

Local anesthesia represents the foundation of pain control in clinical dentistry. Achieving reliable, profound anesthesia requires a thorough understanding of the molecular pharmacology of local anesthetic molecules, the physicochemical behavior of tertiary amines in physiological and acidic tissue microenvironments, the systemic hemodynamic effects of adrenergic vasoconstrictors, and precise anatomical delivery.

---

Molecular Pharmacology and Mechanism of Action

Chemical Architecture: Amides vs. Esters

All clinical local anesthetic molecules share an identical fundamental tripartite molecular structure:

                    BASIC LOCAL ANESTHETIC STRUCTURE

  [Lipophilic Aromatic Ring] ─── [Intermediate Chain] ─── [Hydrophilic Amine]
     (Benzene or Thiophene)        (Ester or Amide)         (Tertiary Amine)
     • Confers lipid solubility    • Determines classification • Confers water solubility
     • Governs potency & uptake    • Site of metabolic cleavage • Accepts H+ for ionization

Local anesthetics are categorized into two major chemical classes based on the linkage of their intermediate chain:

• Esters (-COO- linkage): Include procaine, tetracaine, chloroprocaine, benzocaine, and cocaine. Esters possess one "i" in their generic name (e.g., procaine). They are rapidly hydrolyzed in the bloodstream by plasma pseudocholinesterase (butyrylcholinesterase). A primary metabolic byproduct is para-aminobenzoic acid (PABA), a compound with high allergenic potential responsible for frequent allergic hypersensitivity reactions.
• Amides (-NHCO- linkage): Include lidocaine, articaine, mepivacaine, bupivacaine, and prilocaine. Amides possess two "i"s in their generic name (e.g., lidocaine, articaine). Amides are metabolized predominantly by hepatic cytochrome P450 microsomal enzymes (CYP1A2, CYP3A4), with the notable exception of articaine. True IgE-mediated allergic reactions to amides are extraordinarily rare (<1%); adverse reactions are almost universally caused by psychogenic syncope, accidental intravascular injection, or allergy to the antioxidant preservative sodium bisulfite (added to stabilize epinephrine).

Specific Receptor Theory and Sodium Channel Blockade

Local anesthetics act via the Specific Receptor Theory. Within the nerve axon, voltage-gated sodium (Na+) channels are responsible for the rapid inward sodium influx that generates action potentials during depolarization. Local anesthetics exist in solution in a dynamic chemical equilibrium between the uncharged lipophilic free base (RN) and the charged hydrophilic cationic acid (RNH+):

$\text{RN} + \text{H}^+ \rightleftharpoons \text{RNH}^+$

1. Membrane Translocation: The uncharged, lipophilic free base (RN) is the only form capable of penetrating the lipophilic epineurium, perineurium, and neuronal phospholipid bilayer membrane.
2. Receptor Binding: Once inside the relatively acidic axoplasm (pH ≈ 7.2), the free base re-equilibrates and binds hydrogen ions to reform the charged cation (RNH+).
3. Channel Inactivation: The charged RNH+ cation binds directly to a specific receptor site located in the inner pore/vestibule of the alpha-subunit of the voltage-gated Na+ channel. This locks the channel in an inactivated/closed conformational state, preventing sodium conductance, abolishing threshold potential attainment, and halting the propagation of impulses along the nodes of Ranvier.

---

Henderson-Hasselbalch Kinetics and the Acidic Tissue Dilemma

The ratio of uncharged base (RN) to charged cation (RNH+) is governed by the Henderson-Hasselbalch equation:

$\text{pH} = \text{pKa} + \log\left(\frac{[\text{RN}]}{[\text{RNH}^+]}\right)$

• Dissociation Constant (pKa): The pH at which exactly 50% of the local anesthetic exists as uncharged base (RN) and 50% exists as charged cation (RNH+). The pKa is the primary determinant of onset of action:
  • Low pKa agents (mepivacaine pKa = 7.6, articaine pKa = 7.8, lidocaine pKa = 7.9): At normal physiological tissue pH (7.4), a substantial fraction (15% to 35%) exists as uncharged RN, facilitating rapid membrane penetration and fast clinical onset (2 to 4 minutes).
  • High pKa agents (bupivacaine pKa = 8.1, procaine pKa = 9.1): At pH 7.4, less than 15% exists as uncharged base, resulting in a prolonged clinical onset (5 to 10 minutes).

Failure of Anesthesia in Inflamed and Infected Tissues

When local anesthetic is injected into tissue affected by acute odontogenic infection or purulent abscess, two major biological hurdles prevent adequate anesthesia:

1. Severe Tissue Acidosis: Purulent exudate and active tissue inflammation drive the extracellular microenvironmental pH down to 5.0 to 5.5. Substituting this value into the Henderson-Hasselbalch equation reveals that the equilibrium shifts overwhelmingly toward the cationic RNH+ form. Less than 0.1% to 1.0% of the molecules remain as uncharged lipophilic RN. As a result, virtually no drug can penetrate the nerve sheath, leading to acute anesthetic failure.
2. Inflammatory Hyperemia and Neuroplasticity: Acute inflammation induces local vasodilation and increased capillary perfusion, rapidly washing the local anesthetic out of the tissue. Concurrently, inflammatory mediators (prostaglandin PGE2, bradykinin) upregulate tetrodotoxin-resistant sodium channels (Nav1.8 and Nav1.9) on nociceptive C-fibers, lowering pain thresholds and inducing peripheral sensitization.

---

Vasoconstrictors: Receptor Pharmacology and Maximum Recommended Doses (MRD)

Adrenergic vasoconstrictors (primarily epinephrine) are added to local anesthetic solutions to counteract the intrinsic peripheral vasodilatory properties of amide anesthetics.

Adrenergic Receptor Actions

• alpha-1 Adrenergic Receptors: Located in the vascular smooth muscle of oral submucosa and skin. Stimulation causes intense local vasoconstriction, slowing systemic absorption, reducing peak plasma concentration and toxicity, prolonging the duration of pulpal and soft tissue anesthesia, and providing surgical hemostasis.
• beta-1 Adrenergic Receptors: Located in cardiac myocardium and the SA/AV nodes. Stimulation increases heart rate (positive chronotropy), contractile force (positive inotropy), cardiac output, and myocardial oxygen demand, predisposing to tachyarrhythmias.
• beta-2 Adrenergic Receptors: Located in skeletal muscle vascular beds. Low doses of circulating epinephrine stimulate beta-2 receptors, producing peripheral vasodilation and an initial slight dip in diastolic blood pressure. Rebound hyperemia occurs once alpha-1 stimulation wears off.

Maximum Recommended Doses (MRD) of Epinephrine

Standard dental cartridges in North America and Saudi Arabia contain 1.8 mL of solution (UK/European standard cartridges contain 2.2 mL). Epinephrine 1:100,000 equals 0.01 mg/mL (18 µg or 0.018 mg per 1.8 mL cartridge). Epinephrine 1:200,000 equals 0.005 mg/mL (9 µg or 0.009 mg per 1.8 mL cartridge).

                      EPINEPHRINE DOSING BOUNDARIES

  1. HEALTHY ASA I / II PATIENT: 0.2 mg Maximum
     • 1:100,000 concentration: 0.2 mg / 0.018 mg = 11.1 cartridges
     • 1:200,000 concentration: 0.2 mg / 0.009 mg = 22.2 cartridges

  2. CARDIOVASCULAR / MEDICALLY COMPROMISED PATIENT: 0.04 mg Maximum
     • 1:100,000 concentration: 0.04 mg / 0.018 mg = 2.2 cartridges (STRICT MAX: 2 cartridges)
     • 1:200,000 concentration: 0.04 mg / 0.009 mg = 4.4 cartridges (STRICT MAX: 4 cartridges)

• Cardiac Dose Indications: The 0.04 mg limit applies to patients with ischemic heart disease, prior myocardial infarction (>6 months), coronary artery bypass grafts, congestive heart failure (NYHA Class III/IV), significant cardiac dysrhythmias, uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg), or patients taking non-selective beta-blockers (e.g., propranolol, nadolol).
• Non-Selective beta-Blocker Interaction: Co-administration of epinephrine with non-selective beta-blockers blocks compensatory beta-2 vasodilation, leaving vascular alpha-1 vasoconstriction entirely unopposed. This can precipitate a severe hypertensive crisis accompanied by compensatory reflex bradycardia.

---

Maximum Recommended Doses (MRD) of Dental Local Anesthetics

When calculating local anesthetic limits, the dose must be calculated based on the patient's lean body weight and capped at the absolute manufacturer maximum. The lowest threshold between the local anesthetic MRD and the vasoconstrictor MRD dictates the safe limit.

Clinical Distinctions and Safety Considerations

• Articaine 4%: Features a thiophene ring instead of a benzene ring, conferring exceptional lipid solubility and superior bone penetration (enabling successful primary buccal infiltration for mandibular first molars). Articaine possesses a unique dual metabolic pathway: 90% is rapidly hydrolyzed by circulating plasma carboxylesterases into the inactive metabolite articainic acid, and only 10% undergoes hepatic microsomal metabolism. Consequently, its elimination half-life is extraordinarily short (20 to 30 minutes, compared to 90 minutes for lidocaine), significantly reducing systemic accumulation risks and making it the safest amide in patients with moderate hepatic disease.
• Mepivacaine 3% Plain: Exhibits minimal intrinsic peripheral vasodilatory activity. It is the drug of choice when vasoconstrictors are contraindicated or when treating patients allergic to sulfite preservatives.
• Bupivacaine 0.5%: Highly lipophilic with 95% plasma protein binding. Provides prolonged pulpal anesthesia (>1.5 to 2.5 hours) and extended soft tissue anesthesia (>8 to 12 hours), ideal for post-operative surgical pain management. Cardiotoxicity Warning: Bupivacaine dissociates very slowly from cardiac sodium channels during diastole, causing severe, refractory ventricular arrhythmias. It is strictly contraindicated in young children and mentally handicapped patients due to high rates of severe, self-inflicted soft tissue biting injuries.
• Prilocaine 4% and Methemoglobinemia: Prilocaine is metabolized in the liver and lungs into ortho-toluidine (o-toluidine). o-Toluidine is an oxidizing metabolite that oxidizes ferrous iron (Fe2+) in hemoglobin to the ferric state (Fe3+), generating methemoglobin. Methemoglobin cannot bind oxygen and causes a leftward shift of the oxygen-hemoglobin dissociation curve. Symptoms appear when methemoglobin levels exceed 10%–20%: cyanosis unresponsive to 100% oxygen, dyspnea, fatigue, headache, and classic chocolate-brown colored blood. Management: Administer the specific antidote Methylene Blue at 1 to 2 mg/kg IV of a 1% solution slowly over 5 minutes (acts as an artificial electron transporter, reducing ferric iron back to ferrous iron via NADPH-methemoglobin reductase).

---

Nerve Block Techniques: Anatomy, Landmarks, and Failures

                      MANDIBULAR NERVE BLOCK COMPARISON

       IANB (HALSTED)              GOW-GATES BLOCK           VAZIRANI-AKINOSI
  • Coronoid notch & raphe     • Neck of condyle         • Closed mouth technique
  • 6-10 mm above occlusal     • Below lateral pterygoid • Maxillary MGJ level
  • Bone contact at 20-25 mm   • True V3 block (~95%)    • No bony contact
  • Blocks IAN, lingual, inc   • Slower onset (5-10 min) • For severe trismus

1. Inferior Alveolar Nerve Block (IANB / Halsted Technique)

• Target: Mandibular foramen on the medial surface of the ascending ramus, deep to the lingula.
• Key Anatomical Landmarks:
  1. Coronoid notch: Deepest concavity on the anterior border of the ramus (identifies vertical height of injection).
  2. Pterygomandibular raphe: Vertical tendon representing junction between buccinator and superior pharyngeal constrictor muscles (identifies anteroposterior boundary).
  3. Mandibular occlusal plane: Syringe barrel is placed over the contralateral premolars, directed parallel to and 6 to 10 mm superior to the mandibular occlusal plane.
• Technique and Penetration Depth: Penetrate 20 to 25 mm (two-thirds of a standard 25-gauge long needle) until gentle bony contact is established on the posterior wall of the mandibular sulcus. Withdraw 1 mm, aspirate in two planes, and deposit 1.5 mL (two-thirds to three-quarters of a cartridge) over 60 seconds to anesthetize the IAN. Withdraw the needle halfway (10 to 12 mm), re-aspirate, and deposit 0.2 to 0.3 mL (one-eighth cartridge) to anesthetize the lingual nerve.
• Troubleshooting and Failure Modes:
  • Premature Bony Contact (<15 mm): The needle tip has contacted the internal oblique ridge or temporal crest too anteriorly. Partially withdraw the needle, swing the syringe barrel more anteriorly toward the ipsilateral mandibular canine, advance deeper to pass the bony obstruction, and reposition back over contralateral premolars.
  • Failure to Contact Bone (>25 mm): The needle is inserted too far posteriorly, passing behind the posterior border of the ramus directly into the parotid gland capsule. Deposition of anesthetic here causes transient unilateral facial nerve (CN VII) palsy (inability to close the ipsilateral eyelid, drooping of the labial commissure, loss of motor function; resolves spontaneously in 2 to 4 hours; requires eye lubrication and reassurance).
  • Accessory Innervation: Incomplete molar pulpal anesthesia despite profound lip and chin numbness is frequently caused by accessory innervation from the mylohyoid nerve (which enters accessory foramina on the lingual aspect of the mandible). Solution: Administer 0.5 mL of local anesthetic via lingual infiltration adjacent to the apex of the symptomatic molar. Other sources of failure include bifid mandibular canals, contralateral incisive nerve arborization across the midline, and branches of the cervical plexus (great auricular nerve).

2. Gow-Gates Mandibular Nerve Block

• Target: Condylar neck immediately inferior to the insertion of the lateral pterygoid muscle.
• Landmarks: Extraorally, an imaginary line extending from the corner of the mouth to the intertragic notch of the ear. Intraorally, the mesiolingual cusp of the maxillary second molar.
• Advantages: High success rate (>95%); provides true V3 division blockade, successfully anesthetizing the IAN, lingual, mylohyoid, auriculotemporal, and mental/incisive nerves, as well as the long buccal nerve in ~75% of patients. Lowest incidence of positive intravascular aspiration (1.6% vs. 10%–15% for IANB).
• Disadvantages: Slower clinical onset (5 to 10 minutes) due to large nerve trunk diameter and greater soft tissue volume; requires wide mouth opening.

3. Vazirani-Akinosi Closed-Mouth Mandibular Block

• Indications: Severe trismus, temporomandibular joint ankylosis, or uncooperative patients unable to open the mouth.
• Technique: Patient gently occludes teeth. Needle is advanced parallel to the maxillary occlusal plane at the level of the mucogingival junction of the maxillary second/third molars, penetrating 25 mm into the pterygomandibular space midway between the ramus and maxillary tuberosity without contacting bone.

4. Mental and Incisive Nerve Block

• Target: Mental foramen located in the mucobuccal fold between the apices of the mandibular premolars.
• Protocol: Deposit 0.6 to 0.9 mL outside the foramen. Apply firm digital pressure over the injection site for 2 minutes to force anesthetic solution into the mental canal, blocking the incisive nerve and providing pulpal anesthesia from the mandibular premolars to the central incisor.

5. Posterior Superior Alveolar (PSA) Block and Palatal Injections

• PSA Block: Height of the mucobuccal fold above the maxillary second molar. Needle inserted 45° superiorly, 45° medially, and 45° posteriorly to a maximum depth of 16 mm. Anesthetizes the maxillary molars, with the exception of the mesiobuccal root of the maxillary first molar in ~28% of patients, which is innervated by the Middle Superior Alveolar (MSA) nerve.
• PSA Hematoma Risk: Penetrating deeper than 16 mm or directing the needle too laterally lacerates the pterygoid venous plexus or maxillary artery, causing rapid, massive swelling and a disfiguring cheek hematoma. Immediate management: Firm digital pressure over the infratemporal fossa for 5 minutes, ice application, and patient reassurance.
• Greater Palatine and Nasopalatine Blocks: Target the greater palatine foramen (junction of hard palate and alveolar process palatal to maxillary 2nd/3rd molars) and incisive papilla, respectively. Provide palatal soft tissue and mucoperiosteal anesthesia with zero pulpal effect.

---

Local Anesthetic Systemic Toxicity (LAST)

LAST is a life-threatening medical emergency caused by inadvertent rapid intravascular injection or massive absolute overdose exceeding metabolic clearance capacity.

                      PROGRESSION OF LAST SYMPTOMATOLOGY

  [PHASE 1: PREMONITORY CNS EXCITATION] ──┐
  • Circumoral numbness & tingling        ├── Mild / Moderate Intoxication
  • Metallic taste & tinnitus (ringing)   │   (Inhibitory cortical pathways blocked first)
  • Visual disturbances & agitation       │
  • Muscle tremors & twitches ────────────┘
                  │
                  ▼
  [PHASE 2: SEVERE CNS DEPRESSION] ───────┐
  • Generalized tonic-clonic seizures     ├── Severe Neurotoxicity
  • Respiratory depression & apnea        │   (Excitatory pathways suppressed)
  • Coma & loss of consciousness ─────────┘
                  │
                  ▼
  [PHASE 3: CARDIOVASCULAR COLLAPSE] ─────┐
  • Severe myocardial depression          ├── Fatal Cardiovascular Collapse
  • Bradycardia & conduction blocks       │   (Myocardial sodium channels blocked)
  • Ventricular arrhythmias & asystole ───┘

Emergency Management Protocol for LAST

1. Stop Injection Immediately: Discontinue anesthetic administration, remove syringe, call for emergency medical assistance (Saudi 997 / 911), and note time.
2. Airway and Hyperoxygenation: Maintain a patent airway and administer 100% high-flow oxygen. Hyperventilate the patient to prevent hypoxia, hypercapnia, and acidosis. Acidosis drastically worsens LAST by decreasing local anesthetic protein binding and promoting intracellular ion trapping in the brain.
3. Seizure Management: Administer IV benzodiazepines (e.g., Midazolam 0.05 to 0.1 mg/kg IV or 5 mg IM). Avoid propofol in hemodynamically unstable patients due to worsening myocardial depression.
4. Targeted Antidote — 20% Lipid Emulsion (Intralipid):
   • Mechanism ("Lipid Sink Theory"): Intravenous infusion of a lipid emulsion creates an intravascular hydrophobic lipid compartment that sequesters lipophilic local anesthetic molecules from plasma, reversing drug binding to cardiac and cerebral tissue receptors and accelerating metabolic clearance.
   • Dosing Protocol:
     • Initial IV bolus of 1.5 mL/kg of 20% Lipid Emulsion administered over 2 to 3 minutes (~100 mL for a 70 kg adult).
     • Immediately initiate a continuous IV infusion of 0.25 mL/kg/min.
     • If hemodynamic instability persists, repeat the bolus every 3 to 5 minutes (up to a maximum total dose of 12 mL/kg) and increase the infusion rate to 0.5 mL/kg/min.